Core Viewpoint - Analysts project that Thermo Fisher Scientific (TMO) will report quarterly earnings of $5.22 per share, reflecting a 2.8% decline year over year, with revenues expected to reach $10.65 billion, a 1% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Laboratory Products and Biopharma Services' at $5.74 billion, a decrease of 0.2% year over year [5]. - 'Revenues- Specialty Diagnostics' are projected to reach $1.14 billion, indicating a 2.5% increase year over year [5]. - 'Revenues- Life Sciences Solutions' are expected to be $2.40 billion, reflecting a 2.1% increase year over year [5]. - 'Revenues- Analytical Instruments' are estimated at $1.79 billion, showing a 0.7% increase year over year [6]. - 'Geographic Revenues- Customer Location- North America' is projected at $5.56 billion, a 0.5% increase from the prior year [6]. - 'Geographic Revenues- Customer Location- Asia-Pacific' is estimated at $1.98 billion, reflecting a 0.4% increase year over year [7]. - 'Geographic Revenues- Customer Location- Other regions' is expected to reach $391.38 million, indicating a 3.3% increase year over year [7]. - 'Geographic Revenues- Customer Location- Europe' is projected at $2.69 billion, suggesting a 0.9% increase year over year [8]. Stock Performance - Over the past month, shares of Thermo Fisher have returned +8.3%, outperforming the Zacks S&P 500 composite's +5.4% change [8]. - Currently, TMO holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [8].

Core Viewpoint - Analysts project that Thermo Fisher Scientific (TMO) will report quarterly earnings of $5.10 per share, reflecting a 0.2% decline year over year, with revenues expected to reach $10.25 billion, down 0.9% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating a reassessment by covering analysts [1][2]. - Revisions to earnings estimates are crucial for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [2]. Revenue Projections - Analysts forecast 'Revenues- Laboratory Products and Biopharma Services' to reach $5.61 billion, indicating a decline of 2.1% from the prior-year quarter [4]. - 'Revenues- Specialty Diagnostics' is expected to be $1.10 billion, reflecting a decrease of 0.5% year over year [4]. - 'Revenues- Life Sciences Solutions' is projected at $2.28 billion, showing a year-over-year change of -0.3% [4]. Geographic Revenue Estimates - 'Revenues- Analytical Instruments' is expected to reach $1.73 billion, suggesting a year-over-year increase of 2.5% [5]. - 'Geographic Revenues- Customer Location- North America' is projected at $5.43 billion, indicating a decline of 1.7% year over year [5]. - 'Geographic Revenues- Customer Location- Asia-Pacific' is estimated at $1.88 billion, reflecting a growth of 0.8% [5]. - 'Geographic Revenues- Customer Location- Other regions' is expected to reach $368.42 million, indicating a year-over-year increase of 6.5% [6]. - 'Geographic Revenues- Customer Location- Europe' is projected at $2.60 billion, reflecting a decrease of 0.7% from the year-ago quarter [6]. Stock Performance - Shares of Thermo Fisher have shown a return of -15.7% over the past month, compared to a -6.3% change in the Zacks S&P 500 composite [6].